Skip to content
Subscriber Only

Mylan’s Annual Sales to Be at Low End of Forecast, CFO Says

Mylan Inc., the second-biggest U.S. maker of generic drugs, said its 2013 sales will be at the low end of its forecast of $7 billion to $7.4 billion.

Chief Financial Officer John Sheehan blamed foreign currency exchange rates, though he said the company’s sales would still fall within the range it projected this year. The Canonsburg, Pennsylvania-based drugmaker probably will hit its annual earnings forecast of $2.75 to $2.95 a share excluding some items, Sheehan said today at a presentation.